RDIF brings together the best Russian
and international technologies in the fight
against COVID-19
Production of the first registered
COVID-19 vaccine in the world

The Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against coronavirus.

Sputnik V is based on a safe and tested human adenovirus vector platform. Using two different human adenoviral vectors is a unique approach that allows to boost the immune response and provide long lasting immunity.

The efficacy of the Sputnik V vaccine is confirmed at 91.6  %, the results of a Phase III clinical trial of the vaccine are published in the Lancet, one of the world’s oldest and most respected medical journals. According to analysis of data from 3.8 million vaccinated persons in Russia Sputnik V demonstrates 97.6  % efficacy. The vaccine provides 100  % protection against severe COVID-19.

RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than $10 (Sputnik V is a two dose vaccine). The vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.

Sputnik V vaccine is approved by more than 65 countries worldwide. Sputnik V vaccine is approved by more than 65 countries worldwide.The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.

After the Sputnik V vaccine’s clinical trial preliminary results showed its efficacy at above 90 percent, the Russian Direct Investment Fund and Gamaleya Institute on November 23, 2020 offered AstraZeneca to use one of the two components (human adenoviral vectors) of the Sputnik V vaccine in AstraZeneca’s clinical trials.

AstraZeneca accepted RDIF’s proposal and began clinical trials of its vaccine in combination with Sputnik V’s human adenoviral vector type Ad26. This research will allow AstraZeneca’s scientists to study the possibility of boosting their vaccine’s efficacy through the application of this combined approach.

For more information visit www.sputnikvaccine.com and follow Sputnik V on social networks.

Sputnik Light, a single dose COVID-19 vaccine

The Russian Ministry of Health, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announce that Sputnik Light, a single dose COVID-19 vaccine, has received authorization for use in Russia.

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The single dose Sputnik Light vaccine demonstrated 79.4  % efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.

An efficacy level of almost 80  % is higher than that of many two-dose vaccines.

Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.

Production of antiviral drugs

RDIF and the ChemRar Group have launched the production of Avifavir - the first drug registered in Russia that has demonstrated effectiveness against COVID-19 in clinical trials.

Avifavir is one of the two registered COVID-19 drugs in the world and the first Favipiravir-based drug in the world approved for treatment of COVID-19.

Production of diagnostic tests for the detection of coronavirus

Jointly with Japan’s K.K. Mirai Genomics, RDIF has invested in the production and distribution of the Russian-Japanese diagnostic system EMG - Evotech-Mirai Genomics, which is one of the world’s most accurate and fastest systems for the detection of coronavirus. Results are achieved in just 30 minutes. The Japan Bank for International Cooperation has joined the project through the Russia-Japan Investment Fund.

RDIF announces RDIF. Healthcare

RDIF. Healthcare – an investment channel with a strategic focus on the implementation of projects in the healthcare sector. RDIF has been actively involved in fighting COVID-19 through working on healthcare projects.

Before the pandemic, a number of healthcare projects have been launched as part of the fund’s investment strategy aimed at improving general quality of life. Further development of healthcare investment is the next stage in the process.